New drug combo tested for Tough-to-Treat bile duct cancer
NCT ID NCT05170438
Summary
This study is testing whether combining the drugs lenvatinib and paclitaxel can help control advanced bile duct cancer in patients whose disease got worse after standard gemcitabine-based chemotherapy. It aims to see if this combination can shrink tumors and delay cancer growth. The trial will enroll about 51 patients to measure treatment response, survival time, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
Chang Gung Memorial Hospital
Taoyuan District, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
MacKay Memorial Hospital
Taipei, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.